Aucatzyl is a chimeric antigen receptor (CAR) T-cell therapy, a type of therapy that uses genetic modification to train the ...

With the Oncology Brothers, Uma Borate, MD, discusses how ziftomenib is showing promising results as a targeted therapy for ...

During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed ...

New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated ...

80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- ... Tumor-Induced B Cell Changes Reveal Potential Biomarker for Treatment Response ...

Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...

Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell ...

Huntsman Cancer Institute joins other institutions in myeloMATCH, a program that matches patients with clinical trials that ...

Huntsman Cancer Institute at the University of Utah (the U) has joined other institutions in an innovative clinical trials ...

Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic ...

The promise of CAR-T is undeniable, offering new hope for patients. However, unless the costs are reduced and more patients ...